Bridging the Last Mile of Acute Cardiology: Synthesized 3D Vectorcardiography at Home
Dr. Dereck Mush, MD, MBA
Cardio Diagnostics
Develops epigenetic and genetic blood tests to assess coronary heart disease risk.
What they do
Develops integrated genetic epigenetic clinical blood tests to detect and assess the risk of coronary heart disease. The tests are ordered by primary care clinics and cardiologists to identify patients at risk before clinical events manifest.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Epigenetic cardiac diagnostics
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Chicago, United States
- Region
- North America
- Founded
- 2017
- Total funding
- $15M raised
Notable investors: University of Iowa, Angels.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
The AI ECG Cardiology Market After Queen of Hearts: Who the De Novo Clearance Actually Benefits
Dr. Dereck Mush, MD, MBA
Wearable cardiac monitoring is catching arrhythmias in men who would never have scheduled the test that found them
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA